Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute of Allergy and Infectious Diseases (NIAID) |
---|---|
Information provided by: | National Institute of Allergy and Infectious Diseases (NIAID) |
ClinicalTrials.gov Identifier: | NCT00307125 |
The purpose of this study is to determine whether treatment with rituximab in people who develop new anti-HLA antibodies after kidney transplant will promote longer-term survival of the transplanted kidney.
Condition | Intervention | Phase |
---|---|---|
Kidney Transplantation Kidney Disease Kidney Failure, Chronic |
Drug: Rituximab Drug: Immunosuppressive drugs |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | B-Cell Depletion by Anti-CD20 (Rituximab) in Renal Allograft Recipients Who Develop Early de Novo Anti-HLA Alloantibodies |
Estimated Enrollment: | 134 |
Study Start Date: | March 2006 |
Estimated Primary Completion Date: | March 2014 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
Assignment into a group will occur after Stage 1. Adult participants (18 years of age or older) randomly assigned to Group 1 will receive an intravenous infusion of 1000mg rituximab on Days 0 and 14. Pediatric participants (18 years of age or younger) randomly assigned to Group 1 will receive an intravenous infusion of 375 mg/m2 rituximab (max. 500mg/m2) on Days 0, 8, 15, and 22.
|
Drug: Rituximab
Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma
Drug: Immunosuppressive drugs
Drugs used to prevent the participant's immune system from rejecting the transplanted kidney
|
2: Placebo Comparator
Assignment into a group will occur after Stage 1. Adult participants (18 years of age or older) randomly assigned to Group 2 will receive an intravenous infusion of 1000mg rituximab on Days 0 and 14. Pediatric participants (18 years of age or younger) randomly assigned to Group 2 will receive an intravenous infusion of 375 mg/m2 rituximab (max. 500mg/m2) on Days 0, 8, 15, and 22.
|
Drug: Immunosuppressive drugs
Drugs used to prevent the participant's immune system from rejecting the transplanted kidney
|
Organ rejection occurs when a patient's body does not recognize the new organ and attacks it. Data suggest that the development of anti-human leukocyte antigen (HLA) antibodies is an early clinical indication that organ rejection may occur. Rituximab is a genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously; it is FDA-approved for the treatment of non-Hodgkin's lymphoma. In a previous small study, kidney transplant patients with either acute humoral rejection (AHR) or chronic humoral rejection (CHR) were given rituximab and other antilymphocyte therapy. Patients with AHR had lower or undetectable levels of circulating anti-HLA antibodies after study treatment, and patients with CHR had a sustained decrease of anti-HLA antibodies to undetectable after 6 to 9 months. This new study will evaluate the safety and efficacy of rituximab in preventing organ rejection and promoting long-term survival of donor kidneys in people who undergo kidney transplantation.
The study will last 8 years. The study will enroll participants for 3 years, and patients will participate in the study for 2 to 5 years. This study involves two stages.
Stage 1 begins 3 to 36 months after transplant. During Stage 1, blood collection will occur every 3 months for up to 36 months after transplant to test for anti-HLA antibodies. When these antibodies are detected twice within 1 month, the patient will undergo a baseline kidney biopsy and have his or her glomerular filtration rate (GFR) measured to determine kidney function. If a patient meets certain study criteria, he or she will enter Step 2.
If anti-HLA antibodies are not detected in a patient's blood during Stage 1, the patient's participation will be complete.
In Stage 2, patients will be randomly assigned to one of two study treatment groups:
All participants will also receive standard of care immunosuppressive drugs. Adult participants, 18 years of age or older, will have 9 study visits over 24 months. Pediatric participants, 18 years of age or younger, will have 11 study visits over 24 months. A physical exam, medication history, adverse events assessment, and blood and urine collection will occur at all visits. A biopsy of the kidney transplant will occur at Stage 2 entry and Month 24.
Ages Eligible for Study: | 5 Years to 70 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Stage 1 Inclusion Criteria for All Participants:
Stage 1 Inclusion Criteria for Pediatric Participants (18 Years of Age or Younger):
Stage 2 Inclusion Criteria for Randomization:
Stage 1 Exclusion Criteria for All Participants:
Stage 2 Exclusion Criteria for All Participants:
Contact: Nancy Bridges, MD | nbridges@niaid.nih.gov | |
Contact: Yvonne Morrison, MS | 301-451-3139 | ymorrison@niaid.nih.gov |
United States, Alabama | |
University of Alabama, Pediatric Nephrology | Recruiting |
Birmingham, Alabama, United States, 35294 | |
Contact: Michelle Sharbono, RN michelle.sharbono@chsys.org | |
Principal Investigator: Mark Benfield, MD | |
University of Alabama | Recruiting |
Birmingham, Alabama, United States, 35294 | |
Contact: Veronica Shierling vhshier@uab.edu | |
Principal Investigator: Vineeta Kumar, M.D. | |
United States, California | |
University of California, San Francisco | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Jyette Birnbaum birnbaumj@surgery.ucsf.edu | |
Principal Investigator: Flavio Vincenti, MD | |
University of California, San Francisco | Recruiting |
San Francisco, California, United States, 94143 | |
Contact: Kana Kornsawad kornsawadk@peds.ucsf.edu | |
Principal Investigator: Anthony Portale, MD | |
United States, Florida | |
University of Florida | Recruiting |
Gainesville, Florida, United States, 32601 | |
Contact: Michael McKinney, RN mckinney@peds.ufl.edu | |
Principal Investigator: Vikas Dharnidharka, MD | |
United States, Illinois | |
Northwestern University | Recruiting |
Chicago, Illinois, United States, 60611 | |
Contact: Jane Charette, RN, BSN jane-charette@northwestern.edu | |
Principal Investigator: John Friedewald, MD | |
University of Illinois | Recruiting |
Chicago, Illinois, United States, 60607 | |
Contact: Patricia West, PharmD pwest@uic.edu | |
Principal Investigator: Bruce Kaplan, MD | |
United States, Maine | |
Maine Medical Center | Not yet recruiting |
Portland, Maine, United States, 04102 | |
Contact: Krista Garrison, M.P.H garrik@mme.org | |
Principal Investigator: John Vella, M.D. | |
United States, Maryland | |
Johns Hopkins University | Not yet recruiting |
Baltimore, Maryland, United States, 21205 | |
Contact: Richard Ugarte, MD rugarte1@jhmi.edu | |
Principal Investigator: Richard Ugarte, MD | |
University of Maryland | Not yet recruiting |
Baltimore, Maryland, United States, 21201 | |
Contact: Lalitha Anandagoda, M.P.H lanandag@medicine,umaryland.com | |
Principal Investigator: Abdolreza Haririan, M.D., M.P.H | |
United States, Massachusetts | |
Brigham and Women's Hospital | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Christine Dyer cdyer@partners.org | |
Principal Investigator: Anil Chandraker, MD | |
Massachusetts General Hospital | Recruiting |
Boston, Massachusetts, United States, 02114 | |
Contact: Sandy Debronkart sdebronkart@partners.org | |
Principal Investigator: Nelson Goes, MD | |
Beth Israel Deaconess Medical Center | Recruiting |
Boston, Massachusetts, United States, 02215 | |
Contact: Megan McLean mmclean@bidmc.harvard.edu | |
Principal Investigator: Martha Pavlakis, MD | |
Children's Hospital Boston | Recruiting |
Boston, Massachusetts, United States, 02115 | |
Contact: Leslie Spaneas, RN leslie.spaneas@childrens.harvard.edu | |
Principal Investigator: William Harmon, MD | |
United States, New Jersey | |
Saint Barnabas Medical Center | Recruiting |
Livingston, New Jersey, United States, 07039 | |
Contact: Wendy Christiansen wchristiansen@sbhcs.com | |
Principal Investigator: Francis Weng, MD | |
United States, Oregon | |
Oregon Health Science University | Recruiting |
Portland, Oregon, United States, 97219 | |
Contact: Jean McCormick mccormje@ohsu.edu | |
Principal Investigator: Douglas Norman, MD | |
Legacy Transplant Services | Recruiting |
Portland, Oregon, United States, 97210 | |
Contact: Sheryl Ames sames@lhs.org | |
Principal Investigator: William Bennett, MD | |
United States, Pennsylvania | |
Children's Hospital of Philadelphia | Recruiting |
Philadelphia, Pennsylvania, United States, 19104 | |
Contact: JoAnn Palmer, RN palmer@email.chop.edu | |
Principal Investigator: Kevin Meyers, MD | |
United States, Texas | |
The Methodist Hospital | Recruiting |
Houston, Texas, United States, 77030 | |
Contact: Shari Lynn, R.N., B.S.N slynn@tmhs.org | |
Principal Investigator: Osama Gaber, MD | |
United States, Washington | |
Children's Hospital and Regional Medical Center | Recruiting |
Seattle, Washington, United States, 98105 | |
Contact: Fouad Attia fouad.attia@seattlechildrens.org | |
Principal Investigator: Ruth McDonald, MD |
Principal Investigator: | Mohamed H. Sayegh, MD | Brigham and Women's Hospital |
Principal Investigator: | William Harmon, MD | Children's Hospital Boston |
Study Chair: | Anil Chandraker, MD | Brigham and Women's Hospital |
Responsible Party: | DAIT/NIAID ( Associate Director, Clinical Research Program ) |
Study ID Numbers: | DAIT CTOT-02, CCTPT-02 |
Study First Received: | March 23, 2006 |
Last Updated: | October 6, 2008 |
ClinicalTrials.gov Identifier: | NCT00307125 |
Health Authority: | United States: Food and Drug Administration; United States: Institutional Review Board |
Organ Transplantation Immunosuppression Renal Failure |
Antibodies, Monoclonal Antibodies Renal Insufficiency Urologic Diseases Rituximab |
Renal Insufficiency, Chronic Kidney Failure, Chronic Kidney Diseases Immunoglobulins Kidney Failure |
Immunologic Factors Antineoplastic Agents Therapeutic Uses |
Physiological Effects of Drugs Antirheumatic Agents Pharmacologic Actions |